Related Experiment Video
Updated: Mar 25, 2026

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
Published on: January 5, 2024
Cancer-Associated Venous Thromboembolism
Hazem Elewa1, Riham Elrefai2, Geoffrey D Barnes3
1College of Pharmacy, Qatar University, PO Box 2713, Doha, Qatar.
Opinion Statement:
Cancer patients are at high risk for venous thromboembolism (VTE) which is considered the second leading cause of death among this population. Both cancer and cancer treatment increase this risk. Since the risk of VTE is not the same in all cancer patients, it is important to understand what factors increase the risk of incident and the risk of recurrent VTE in this patient population. In an effort to combine multiple factors into a single risk stratification system, a scoring system for recurrent VTE risk in cancer patients has been developed and externally validated. While vitamin K antagonists (VKA) or the direct oral anticoagulants (DOACs) are first-line therapies for non-cancer-associated VTE treatment, low-molecular-weight heparin (LMWH) agents are the first-line anticoagulant for treatment of cancer-associated VTE. In this review, we discuss the epidemiology, pathophysiology, and risk stratification used in cancer-associated VTE. We also discuss the current therapies for cancer-associated VTE and the evidence supporting their use from the literature.
More Related Videos
Related Concept Videos
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Cancer
Varicose Veins II: Diagnostic Studies and Interprofessional Care

